The balance between proliferation and apoptosis is represented by changes in the expression of the tissue markers, Bcl-2 and p53, and the presence of silverstained nucleolar organizing regions (AgNOR) on DNA in prostate adenocarcinomas. Identifying a mathematical model that would take into account the opposing nature of both processes and relate this to cancer stage and grade would be a useful adjunct for studying disease behaviour. This retrospective study investigated tissue marker expression in prostate adenocarcinoma biopsy samples from 17 patients. Staining for p53 was inversely correlated with patient age. Staining for Bcl-2 correlated with the presence of advanced metastatic cancer and American Joint Committee on Cancer (AJCC) disease stage. A mathematical model was developed which combined coded staining intensity data for Bcl-2 and AgNOR, as markers of proliferation, and for p53, as a marker of apoptotis. The mathematical model significantly correlated with Gleason score, AJCC stage and serum prostate specific antigen level, whereas each tissue marker alone did not correlate with all these measures.
Introduction
Prostate cancer is among the most common cancers in Slovenia. 1 According to the Slovenian cancer registry, the incidence of prostate cancer was approximately 85/100 000 men in 2006. 1 Prostate cancer is also the second most common malignancy worldwide. 2 The criteria available for the diagnosis and prognosis of prostate cancer, such as stage assessment, prostate specific antigen (PSA) levels and Gleason histological scoring, 3 often do not sufficiently predict the course and outcome of this disease. 4 -7 Some tissue markers play an important role in the detection and identification of prostate cancer. 8 Knowledge of the predictive value of tissue markers would increase understanding of this disease, improve staging, enable earlier detection of prostate cancer in cases of false-negative diagnoses or help in choosing optimal treatment.
Tumour growth depends on disrupted control of cellular growth (proliferation) M Munda, T Hajdinjak, R Kavalar et al. Tissue markers predictive of prostate cancer characteristics and/or cellular death (apoptosis). In prostate cancer tumours, as in other tumours, the balance between these two processes is lost, mostly due to increased cellular proliferation. 9 Cellular proliferation and apoptosis can be determined by various tissue markers, such as p53, which is a tumour-inhibitory protein. Induction of the gene that encodes p53 controls or stops the cellular cycle of damaged cells and, if required, directs the cell to undergo apoptosis, acting to prevent irreparable cells from reproducing. 10, 11 In cancerous cells, the p53 gene is mainly mutated 12 and, as a result, cancerous cells divide uncontrollably. Miyake et al. 13 reported that p53 expression could predict biochemical recurrence following radical prostatectomy. Bcl-2 is an inhibitor of apoptosis 14 that acts in conjunction with p53. 15, 16 The loss of repression of Bcl-2 transcription due to nonfunctional or absent p53 can lead to an excessive formation of Bcl-2 protein 17 which inhibits apoptosis and promotes cell survival. 18 Concato et al. 19 concluded that Bcl-2 and the density of small vessels are independent predictive markers of the prognosis of prostate cancer. AgNOR, a synonym for silver-stained nucleolar organizing regions (NORs) of DNA located on the short ends of acrocentric chromosomes, are emphasized in actively proliferating cells. 20, 21 The NORs can serve as indicators of differentiation of high/low malignant tumours, 22 or as a prognostic factor in some other tumours. 23 Together with clinical data, the findings of different studies show that some tissue molecular markers can be linked with improved predictions for the outcome of prostate cancer, 1,24 -27 especially in terms of recurrence after radical prostatectomy. 28 The aim of the present study was to examine the role of three tissue markers, p53, Bcl-2 and AgNOR, in prostate cancer and their relationship with the clinical data. By including these three tissue markers in a mathematical model, which took account of the opposing roles of the biological processes involved (apoptosis and proliferation), the present study evaluated whether the model was better than each tissue marker alone at predicting any relationships between these combined tissue markers and clinical characteristics.
Patients and methods

PATIENTS AND SPECIMENS
In this retrospective pilot study, needle prostate biopsy specimens from patients with prostate adenocarcinoma were randomly selected by means of classic histology, histochemistry and immunohistochemistry and analysed. Patients' age, Gleason score, serum PSA level (before needle biopsy), the presence of advanced metastatic disease (yes/no) and patients' status according to the American Joint Committee on Cancer (AJCC) 29 were recorded. Patients with stages 2 and 4 prostate adenocarcinoma were included in the study. Cases with incomplete data sets were excluded from the analysis.
IMMUNOHISTOCHEMISTRY
The paraffin-embedded biopsy tissue blocks were cut into 4 µm sections, deparaffinized and rehydrated. The tissue sections were then incubated overnight at 4°C in a moist chamber with one of the following primary antibodies: mouse monoclonal antihuman p53 (Dako, Glostrup, Denmark) at a 1:50 dilution and rabbit monoclonal anti-Bcl-2 (Dako) at a 1:200 dilution. Protein staining was visualized using a labelled streptavidinbiotin-horseradish peroxidase kit (LSAB ® System-HRP; Dako) according to the manufacturer's instruction. Tissue sections were counterstained using Mayer's Tissue markers predictive of prostate cancer characteristics haematoxylin. The negative control for each marker was mouse or rabbit serum IgG instead of primary antibody. The positive controls were sections of colon cancer positive for p53 expression and sections of human basal cells within benign prostatic glands positive for Bcl-2 expression. Positive immunohistochemical reactions were characterized as a dark brown reaction colour showing nuclear staining for p53 and cytoplasmic staining for Bcl-2.
Using a histochemical AgNOR technique, nucleolar organizing DNA regions on the short ends of acrocentric chromosomes were stained to visualize acid proteins. Briefly, tissue sections were deparaffinized and then soaked in a silver nitrate (Merck, Darmstadt, Germany) in acid gelatine aqueous medium solution, using a method adapted from Ploton et al. 30 
MORPHOMETRY
Quantitative analyses of tissue sections for p53 and AgNOR immunohistochemical staining were performed using a Leica DM 2500 microscope with a Leica DFC320 video camera and a Leica QWIN V3 Std computer program (Leica Microsystems, Wetzlar, Germany). At least 1000 tumour cells were counted per patient. The extent of p53 nuclear staining was expressed using a four-point scale of: 0, no immunoreaction; 1, 1 -33% positive nuclear staining; 2, 34 -67% positive nuclear staining; and 3, 68 -100% positive nuclear staining. Scores of 0 and 1 (0 -33%) were grouped together and classified as low-staining, and scores of 2 and 3 (34 -100%) were grouped as high-staining. For quantitative analysis of AgNOR staining, 100 nuclei per patient specimen were counted and expressed as the mean number of positive-stained grains per nucleus per patient specimen.
Semi-quantitative analysis was performed for the Bcl-2 staining. The intensity of Bcl-2 cytoplasmic staining was estimated using a four-point scale of: 0, no immunoreaction; 1, weak diffuse cytoplasmic staining; 2, moderate to strong granular cytoplasmic staining; and 3, strong staining. The staining intensity for Bcl-2 was further divided into a group classified as high intensity staining (2 -3 on the four-point scale) and a group of low intensity staining (0 -1 on the four-point scale), with the aim of testing the relevance of such reclassification relative to the original scores.
MATHEMATICAL MODEL
A mathematical model was developed that evaluated the staining for the proliferative (Bcl-2 and AgNOR) and apoptotic markers (p53) and related it to the stage and grade of prostate adenocarcinoma. In this model, the coded staining intensity of p53 in the two groups (low/high), Bcl-2 in the two groups (low/high), and AgNOR expressed as ln(p53) -ln(Bcl-2) -2 × ln(AgNOR) were analysed. A more negative value was indicative of increased cellular proliferation and a more positive value (i.e. closer to zero) was indicative of a reduction in proliferation. The model was correlated with clinical and histopathological variables and individual markers. Data transformations were performed using logarithms according to Bland and Altman. 31 
STATISTICAL ANALYSIS
Statistical analysis was carried out using the SPSS ® statistical package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Correlations between the three individual tissue markers and already known prognostic factors (patients' age, Gleason score, PSA level, the presence of advanced metastatic cancer and AJCC stage), and between individual markers, clinical data and the output of the mathematical model were M Munda, T Hajdinjak, R Kavalar et al. Tissue markers predictive of prostate cancer characteristics analysed using Spearman's rank correlation coefficient. A P-value < 0.05 (two tailed) was considered to be statistically significant.
Results
Needle prostate biopsy specimens were available from 17 patients with prostate adenocarcinomas aged 59 -86 years (mean 72 years). The Gleason scores were 6 -9 (mean 7) and the PSA levels were 3.8 -37.2 ng/ml (mean 17.5 ng/ml). Clinical follow-up was available for all 17 patients.
The extent of p53 staining using the fourpoint scale was significantly negatively correlated with patients' age (P = 0.022; Fig.  1 ) and when categorized into low-and highstaining groups (P = 0.042) (data not shown). The intensity of Bcl-2 staining was significantly positively correlated with the presence of advanced metastatic cancer (P = 0.046) and, when categorized into low-and high-intensity staining groups, was also highly correlated with the presence of advanced metastatic cancer (P = 0.004) and AJCC disease stage (P = 0.041) (data not shown). The AgNOR staining values ranged from 1.20 to 2.25 (mean 1.80) positivelystained grains per nucleus per patient specimen and, as a stand-alone marker, AgNOR staining did not show any significant correlation with any clinical data.
When the staining data for the proliferative markers, Bcl-2 and AgNOR, and for the apoptotic marker, p53, were input into the mathematical model, a statistically significant negative correlation was seen with Gleason score (P = 0.0280; Fig. 2A ), AJCC stage (P = 0.0031; Fig. 2B ) and PSA level (P = 0.0369; Fig. 2C ).
Discussion
Knowledge of the balance between proliferation and apoptosis, and their markers, may provide an explanation of tumour dynamics and, therefore, lead to the ability to predict tumour aggressiveness and PSA value C Tissue markers predictive of prostate cancer characteristics disease outcome. Tissue markers may also enable a more detailed definition of an individual's risk for a particular disease course. As a result of the considerable amount of conflicting evidence from studies on the role of tissue markers, especially for the most commonly studied markers, p53 and Bcl-2, no tissue marker has moved from the research setting into the routine clinical assessment of prostate carcinoma. 8 In the present pilot study, p53 was shown to be negatively correlated with patients' age, meaning that p53 expression decreased with increasing age. On the basis of these results, it could be predicted that there is less apoptosis in elderly patients with prostate carcinoma than in younger patients. Less apoptosis may also be related to apparent higher levels of PSA observed in elderly patients without a diagnosis of prostate carcinoma, 32 although this remains to be established. How p53 expression, PSA level and the disease course of prostate cancer interact with each other needs to be studied further, especially when taking into consideration results that show that p53 expression following radical prostatectomy significantly predicts recurrence of the disease, 24 and the evidence that pre-operative patients who are p53-negative have a good prognosis within a longer period following radical prostatectomy. 8 In studies in patients undergoing radical prostatectomy 33, 34 and in patients after radiation therapy failure, p53 was found to be a prognostic factor 35 and could be a useful prognostic marker, although the methods used and the patients included in these studies were not comparable with the present study. When p53 was used in the mathematical model, it significantly correlated with the Gleason score, AJCC stage and PSA level, but when used alone it was only negatively correlated with patient age.
A significant correlation was observed between a higher intensity of Bcl-2 staining and a higher frequency of advanced metastatic cancer. The Bcl-2 staining, divided into two groups (low-and high-intensity), was highly correlated with the presence of advanced metastatic cancer and also with the AJCC disease stage. These results were in accord with studies of surgically-treated prostate cancer showing that Bcl-2 was an important or independent predictor in prostate cancer behaviour. 24, 28 Concato et al. 19 also concluded that Bcl-2 was an independent prognostic marker. The relationship between the intensity of Bcl-2 staining and AJCC stage and the presence of advanced metastatic cancer demonstrated in the present study suggests that Bcl-2 should be studied in a larger sample of patients in order to determine its role as a potential prognostic marker. Stackhouse et al. 36 established that p53 and Bcl-2 tissue markers appear to be important for predicting the behaviour of prostate cancer when prostatectomy specimens were analysed, but not when prostate biopsies were analysed. Dhir et al. 37 analysed the novel prostate cancer marker early prostate cancer antigen (EPCA) and concluded that earlier findings, using biomarkers in prostate biopsies, would provide more prognostic information that could help inform clinicians' decisions. Chin and Reiter 26 suggested that combinations of markers could hopefully enable physicians more rationally to facilitate counselling and direct management for men with prostate cancer. In order to obtain earlier prognostic findings and to use combinations of markers, three biopsy tissue markers were included in the mathematical model used in the present study; one marker of apoptotis (p53) and two markers of proliferation (Bcl-2 and AgNOR). As a result, the outcome value of the model was based on the potency of apoptosis versus the potency of proliferation. The model showed increasingly negative values as Tissue markers predictive of prostate cancer characteristics proliferation increased, with values moving towards zero when proliferation was reduced.
The values from the mathematical model significantly correlated negatively with Gleason score, AJCC disease stage and PSA levels. This suggests a possible connection between Gleason score, AJCC disease stage and PSA levels, and is in accord with findings from other studies, 1, 13, 24 although they only studied the markers separately. With the present mathematical model, the influence of proliferative and apoptotic factors on prostate cancer differentiation were integrated and quantitated, and showed that the model was better able to predict the relationships between tissue marker expression and the clinical data than either of the tissue markers alone.
A study by Sakr et al. 38 using 20 specimens showed a significant correlation between AgNOR expression and Gleason score, and concluded that AgNOR could be a marker of tumour differentiation. In the present study, AgNOR staining only showed a correlation with Gleason score, AJCC stage and PSA level when used in the mathematical model in combination with p53 and Bcl-2 but, as a stand-alone marker, AgNOR staining did not show any significant correlation with any clinical data.
The proliferative and apoptotic markers used in the present mathematical model showed a correlation with Gleason score, AJCC stage and PSA value but, with the exception of Bcl-2, there were no correlations when the tissue markers were examined on their own. On the basis of these results, it may be concluded that the mathematical model could have prognostic value in prostate cancer. It is, therefore, intended to evaluate this mathematical model using a larger group of patients and to include newer tissue markers such as CD105, which is an important marker for angiogenesis, 39 caveolin-1, which is connected with disease outcome, 1, 40 EPCA, which could identify individuals with prostate cancer as much as ≥ 5 years earlier than the current diagnostic approach, 37 and Ki-67, which according to Miyake et al. 13 contributes to the correct prediction of biochemical recurrence following radical prostatectomy. All investigated tissue markers, if found to be significant in correlation analyses, will be included in a multiple regression model to determine independent prognostic factors for patients with prostate cancer, or to demonstrate significance when used in a mathematical model such as the one described in the present study. The authors aim to maximize the prognostic value of prostate cancer tissue markers in order to develop an applicable model that might be used in clinical practice.
